Real-World Incidence of Immune-Related Adverse Events Associated with Nivolumab Plus Ipilimumab in Patients with Advanced Renal Cell Carcinoma: A Retrospective Observational Study

Real-world incidence of immune-related adverse events (irAEs) associated with nivolumab plus ipilimumab in patients with renal cell carcinoma (RCC) has been rarely demonstrated. The present study aims to report the safety outcomes of this combination therapy in the real-life population. We conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Washino, Satoshi, Takeshita, Hideki, Inoue, Masaharu, Kagawa, Makoto, Soma, Takahiko, Yamada, Hodaka, Kageyama, Yukio, Miyagawa, Tomoaki, Kawakami, Satoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541457/
https://www.ncbi.nlm.nih.gov/pubmed/34682890
http://dx.doi.org/10.3390/jcm10204767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541457/
https://www.ncbi.nlm.nih.gov/pubmed/34682890
http://dx.doi.org/10.3390/jcm10204767

Ejemplares similares